摘要
目的观察磷酸化蛋白激酶B(p-AKT)和磷酸化哺乳动物雷帕霉素靶蛋白(p-mTOR)因子在肾透明细胞癌组织中的表达变化,为mTOR及AKT抑制剂应用于肾透明细胞癌的治疗提供依据。方法用免疫组化染色测定肾透明细胞癌和正常肾组织中p-AKT和p-mTOR的表达情况。结果p-AKT在肾透明细胞癌和正常肾组织中的阳性表达率分别为61.3%、26.1%(P<0.01),p-mTOR的阳性表达率分别为56.0%、28.3%(P<0.05)。p-AKT表达与肿瘤临床分期明显相关,临床分期越高,其阳性表达率越高(P<0.05)。p-mTOR蛋白表达与肿瘤临床分期也具有相关性(P<0.05)。肾透明细胞癌组织中p-AKT与p-mTOR的表达呈正相关(r=0.953,P=0.000)。结论AKT/mTOR信号通路在肾透明细胞癌组织中被过度激活。理论上,应用mTOR及AKT抑制剂可治疗肾透明细胞癌。
Objective To explore the expression of p-AKT and p-roTOR factors in clear cell carcinoma of kidney and to provide evidence for mTOR and AKT inhibitors used in renal clear cell carcinoma therapy. Method The expression of p-AKT and p-roTOR in clear cell carcinoma of kidney and normal kidney tissue were measured by immunohistochemical method. Results The level of p-AKT and p-mTOR and expression in renal clear cell carcinoma were significantly higher than that in normal kindney tissues （ P 〈 0.01 and 0.05 ）. The expression of p-AKT significantly associated with tumor clinical stage and the higher the clinical stage, the higher the rate of positive expression of p-AKT （ P 〈 0.05 ）. The expression of p-roTOR protein was relative with tumor clinical stage （P 〈0.05）. The expression of p-AKT in renal clear cell carcinoma was positively correlated with p-roTOR （ r = 0. 953, P = 0.000）. Conclusions AKT/roTOR signaling pathway is over- activated in renal clear ceil carcinoma. In theory,the mTOB. and AKT inhibitors can be used to treat the renal cell carcinoma.
出处
《山东医药》
CAS
北大核心
2009年第46期7-8,共2页
Shandong Medical Journal
关键词
肾肿瘤
肾透明细胞癌
磷酸化蛋白激酶B
磷酸化哺乳动物雷帕霉素靶蛋白
renal cell carcinoma
renal clear cell carcinoma
phosphorylated protein kinase B
phosphorylated mammalian target of rapamycin
